Trial Profile
A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Bupropion (Primary) ; Venlafaxine
- Indications Depression
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 23 May 2011 Planned number of patients changed to 546.
- 23 May 2011 Status changed from not stated to completed.
- 05 Nov 2010 New trial record.